Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts

GlobeNewswire September 24, 2018

Aclaris Therapeutics to Attend Upcoming Investor Conferences

GlobeNewswire September 21, 2018

Aclaris Therapeutics to Highlight Drug Discovery Targeting the Human Kinome at 16th Annual Discovery on Target Meeting

GlobeNewswire September 17, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 5, 2018

Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in the Journal Cancer Research

GlobeNewswire August 21, 2018

Aclaris Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments

GlobeNewswire August 3, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 2, 2018

Aclaris Therapeutics to Announce Second Quarter 2018 Financial Results on August 3, 2018

GlobeNewswire July 26, 2018

FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata

GlobeNewswire July 9, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire July 3, 2018

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

GlobeNewswire June 28, 2018

Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

GlobeNewswire June 26, 2018

Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer

GlobeNewswire June 15, 2018

Phase 3 data in the online Journal of the American Academy of Dermatology show Aclaris' ESKATA™ is safe and effective in treating persons with raised seborrheic keratoses

GlobeNewswire June 12, 2018

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 4, 2018

Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA

GlobeNewswire May 30, 2018

Landec Corporation to Nominate Two New Board Directors

GlobeNewswire May 24, 2018

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Benzinga.com  May 19, 2018

Aclaris Therapeutics Announces Poster Presentations at International Investigative Dermatology 2018 Meeting

GlobeNewswire May 16, 2018

Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting

GlobeNewswire May 15, 2018